What is Psyomics?
Founded in March 2015 by Professor Sabine Bahn of the University of Cambridge and CEO Dan Cowell, Psyomics is at the forefront of improving the speed and accuracy of identifying and diagnosing mental health challenges. Leveraging advanced technology and scientific research, the company aims to revolutionize psychiatric assessment, providing clinicians with more precise tools for patient care. Psyomics operates within the burgeoning health technology market, a sector increasingly recognized for its potential to drive significant advancements in healthcare.
How much funding has Psyomics raised?
Psyomics has raised a total of $10M across 3 funding rounds:
Unspecified
$2M
Unspecified
$2.9M
Other Financing Round
$5.1M
Unspecified (2020): $2M with participation from Cambridge Enterprise, Martlet, Jonathan Milner, and Parkwalk Advisors Limited
Unspecified (2022): $2.9M led by Parkwalk
Other Financing Round (2024): $5.1M supported by Parkwalk Advisors
Key Investors in Psyomics
Parkwalk Advisors
Parkwalk Advisors is a prominent venture capital firm specializing in university spinouts and deeptech innovations. They focus on providing crucial funding and strategic support to early-stage companies emerging from leading academic institutions, particularly in the UK.
Cambridge Enterprise
Cambridge Enterprise is the commercialization arm of the University of Cambridge. They support the development and spin-out of businesses based on research conducted at the university, providing investment and expertise to translate academic discoveries into market-ready solutions.
Martlet
Martlet is an angel investment group that focuses on supporting early-stage technology companies. They provide seed funding and mentorship to promising startups, often with a particular interest in innovative ventures originating from academic research.
What's next for Psyomics?
The recent major strategic investment signals a pivotal growth phase for Psyomics. This capital is expected to accelerate the company's product development, expand its market reach, and further solidify its position as a leader in mental health diagnostics. With a clear trajectory supported by consistent backing, Psyomics is poised to scale its operations and introduce innovative solutions to a global market, addressing critical unmet needs in mental healthcare.
See full Psyomics company page
